The Wall Street Journal: FDA nominee Scott Gottlieb plans recusals from decisions on many drug firms

The Trump administration’s nominee to lead the Food and Drug Administration plans to recuse himself for a year from FDA decisions on more than 20 companies, including some drug giants.

Scott Gottlieb in recent years has held positions and received millions of dollars in income as adviser, executive, paid speaker or consultant to the companies, according to financial-disclosure documents he has filed with government ethics officials.

Read:Here’s a closer look at FDA commissioner nominee Scott Gottlieb’s significant corporate ties

Among the companies are cancer-therapy startups, such as Cell Biotherapy Inc., and large concerns, such as GlaxoSmithKline PLC GSK, -0.08% and Bristol-Myers Squibb Inc.

>>> Original Source <<<